# IRWD — Ironwood Pharmaceuticals · catalysts, narrative & risks

**Deep-research report — K3vl4r**  
**Symbols:** IRWD  
**Sources:** 21  
**Published:** 2026-10-03  
**Canonical:** https://app.k3vl4r.com/research/deep-research-irwd-ironwood-pharmaceuticals-catalysts-narrative-risks-5900

---

## Overview / Current Snapshot (as of 2026-10-03)

Ironwood Pharmaceuticals (Nasdaq: IRWD) is a Boston-based, GI-focused biopharmaceutical company whose commercial business is anchored by LINZESS (linaclotide), marketed in the U.S. through an AbbVie collaboration and internationally under CONSTELLA via AstraZeneca/partners [[14]](https://stockanalysis.com/stocks/irwd/), [[18]](https://www.marketbeat.com/stocks/NASDAQ/IRWD/). The stock closed at ~$3.64 on October 2, 2026 (down ~3.2% that day), with a market cap of ~$601.5M, a 52-week range of $1.41–$5.78, a P/E of ~4.6–4.7, and low beta (~0.21) [[14]](https://stockanalysis.com/stocks/irwd/), [[18]](https://www.marketbeat.com/stocks/NASDAQ/IRWD/), [[21]](https://finance.yahoo.com/quote/IRWD/). The shares have clearly come off their recent highs after a sharp mid-2026 rally.

## Key Recent Catalysts (July–October 2026)

---

_Preview only. The complete multi-source deep-research report — full thesis, evidence, and citations — is available at https://app.k3vl4r.com/research/deep-research-irwd-ironwood-pharmaceuticals-catalysts-narrative-risks-5900 (free to sign up)._
